Overview

A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression

Status:
Completed

Trial end date:
2018-02-16

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the efficacy of intranasal esketamine plus an oral antidepressant compared with an oral antidepressant (active comparator) plus intranasal placebo in delaying relapse of depressive symptoms in participants with treatment-resistant depression (TRD) who are in stable remission after an induction and optimization course of intranasal esketamine plus an oral antidepressant.

Phase:

Phase 3

Details

Lead Sponsor:

Janssen Research & Development, LLC

Treatments:

Antidepressive Agents
Citalopram
Dexetimide
Duloxetine Hydrochloride
Esketamine
Sertraline
Venlafaxine Hydrochloride